PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-1.14
OCF/share of $3–5 – Solid range. Seth Klarman would ensure the company can fund growth and dividends internally.
-1.15
FCF/share $2–3 – Adequate. Seth Klarman might see if incremental growth can lift free cash flow further.
-0.47%
Negative ratio while RVPH is 0.00%. Joel Greenblatt would question whether the firm’s OCF is negative or capex is abnormally large.
0.86
Ratio of 0.86 while RVPH is zero. Bruce Berkowitz might see a small but meaningful advantage in real cash coverage.
No Data
No Data available this quarter, please select a different quarter.